SUO held in conjunction with the AUA Annual Meeting
Saturday, May 17, 2014
Orange County Convention Center
W330

SUO Reception and Dinner
Hyatt Regency Orlando
Regency Grand Ballroom O
Orlando, Florida
SBUR/SUO: The New Landscape of Therapy for Advanced Prostate Cancer
7:50 a.m. – 11:30 a.m.

7:50 a.m. – 8:00 a.m. Introduction
David F. Jarrard, MD
Jill A. Macoska, PhD

8:00 a.m. – 9:20 a.m. Session 1: Castrate Resistant Prostate Cancer (CRPC): New Mechanisms and Therapeutics
Moderators: David F. Jarrard, MD
Jill A. Macoska, PhD

8:00 a.m. – 8:15 a.m. Intracrine Androgen Metabolism: New Targets for Treatment Directed Against Androgen Receptor Action
James L. Mohler, MD

8:15 a.m. – 8:30 a.m. Resistance to Therapy: Approaches in the Clinic
Charles J. Ryan, MD

8:30 a.m. – 8:45 a.m. Novel Strategies for Targeting the AR-Splice Variants
Scott M. Dehm, PhD

8:45 a.m. – 9:00 a.m. Targeting the Androgen Receptor N-Terminus (A Novel Target in a Proven Prostate Cancer Pathway)
Marianne Sadar, PhD

9:00 a.m. – 9:20 a.m. Questions and Panel Discussion
Moderator: Joel B. Nelson, MD

9:20 a.m. – 10:50 a.m. Session 2: CRPC New Mechanisms and Therapeutics
Moderators: David F. Jarrard, MD
Jill A. Macoska, PhD

9:20 a.m. – 9:35 a.m. Long Noncoding RNA Control of Androgen Receptor in CRPC
Christopher P. Evans, MD, FACS

9:35 a.m. – 9:50 a.m. What's New in Immune Therapy
Eugene D. Kwon, MD

9:50 a.m. – 10:05 a.m. Predictors of Survival in Men With CRPC
Christopher J. Logothetis, MD

10:05 a.m. – 10:20 a.m. Small Cell Carcinoma \ Markers of CRPC
Angelo DeMarzo, MD, PhD

10:20 a.m. – 10:50 a.m. Questions and Case Discussions: Integration, Sequencing and Cross Resistance of New Systemic Therapies in CRPC
Moderator: Adam S. Kibel, MD

10:50 a.m. – 11:00 a.m. Break

11:00 a.m. – 11:30 a.m. Coffey Lecture
Kenneth J. Pienta, MD is a medical oncologist who has spent a career treating CRPC. He was the PI of the Prostate SPORE at Michigan for ~15 years and directed the GU oncology program in the cancer center prior to a recent move to Johns Hopkins, where he now directs Urology Research. Ken has authored or co-authored >300 clinical or basic research papers largely focused on CRPC. His recent research is focused on mobilization of cancer stem cells for increased exposure to chemotherapeutic agents, and the role(s) of tumor-associated macrophages in prostate cancer progression and metastasis. He is actually a former student of Don Coffey.

11:30 a.m. – 12:30 p.m. SUO Business Meeting
Luncheon (SUO Members Only)

2014 SUO at the AUA Meeting
12:30 p.m. – 5:00 p.m.

12:30 p.m. – 12:35 p.m. Welcome and Introductions
Program Overview
David F. Jarrard, MD

12:35 p.m. – 1:00 p.m. Prostate Cancer Foundation Young Investigator Program
Stuart Holden, MD

12:40 p.m. – 1:00 p.m. Whitmore Lecture: Outing the Outliers
Mark S. Soloway, MD

Mark Soloway, MD has devoted himself to the subspecialty of urologic oncology for the past 40 years. He has made significant contributions to the understanding and treatment of the three most common GU cancers – prostate, bladder and kidney. Dr. Soloway received the Gold Cystoscope Award from the AUA in 1984. He was presented with a Presidential Citation from the AUA in 2000 – in part for his emphasis on the case presentation method to enhance the interactive aspect of urology meetings. Dr. Soloway chaired the SIU and ICUD bladder cancer recommendations in 2004 and 2011. He is a professor in the department of urology at the University of Miami in Florida. He has authored over 500 articles in peer reviewed journals.

1:00 p.m. – 2:05 p.m. High Risk Localized Prostate Cancer
Moderator: James A. Eastham, MD

1:00 p.m. – 1:10 p.m. Imaging and Evaluation of the High Risk Patient
Samir S. Taneja, MD
1:10 p.m. – 1:20 p.m.  What’s New in Radiation for High Risk Prostate Cancer  Ronald C. Chen, MD, MPH

1:20 p.m. – 1:30 p.m.  Neoadjuvant Approaches for High Risk Prostate Cancer  Bruce Montgomery, MD

1:30 p.m. – 1:40 p.m.  Urologic Cancer Survivorship  Andrew C. Peterson, MD

1:40 p.m. – 2:05 p.m.  Case Discussion and Questions  Moderator:  James A. Eastham, MD

2:05 p.m. – 2:20 p.m.  Renal – RCC Heterogeneity: Clinical and Scientific Implications  Moderator:  Robert G. Uzzo, MD

2:05 p.m. – 2:20 p.m.  Debate: Renal Biopsy – Is Heterogeneity Clinically Relevant  Moderator:  Robert G. Uzzo, MD

2:20 p.m. – 2:35 p.m.  Genetic Heterogeneity and the Branched Evolution of Renal Cancer  James J. Hsieh, MD, PhD

2:35 p.m. – 2:50 p.m.  Predictive Models for Cytoreduction  E. Jason Abel, MD

2:50 p.m. – 3:05 p.m.  Tyrosine Kinase Inhibitor Response Heterogeneity – From Consolidation to Second Line  Robert A. Figlin, MD

3:05 p.m. – 3:20 p.m.  Anti-PD1 Agents in Kidney Cancer  David McDermott, MD

3:20 p.m. – 3:30 p.m.  Break

3:30 p.m. – 5:00 p.m.  Bladder – Multidisciplinary Therapy of Locally Advanced Urothelial Cancer – Clinical Stage T2-T4  Moderator:  Seth P. Lerner, MD

3:30 p.m. – 4:20 p.m.  Clinical Stage T2: Low-Risk

3:30 p.m. – 3:40 p.m.  Neoadjuvant Chemotherapy For All or Is Risk Stratification Validated?  Colin P.N. Dinney, MD (yes)  Michael S. Cookson, MD (no)

3:40 p.m. – 3:50 p.m.  How to Improve Delivery of Neoadjuvant Chemotherapy  Arlene O. Siefker-Radtke, MD

3:50 p.m. – 4:00 p.m.  The Effect of Surgical Quality on Lymph Nodes and Margins  Robert S. Svatok, MD

4:00 p.m. – 4:10 p.m.  T2N1: Role of Adjuvant Therapy versus Observation  Eric Winquist, MD

4:10 p.m. – 4:20 p.m.  Role for Chemoradiation Therapy as Part of Complete Informed Consent  Jason A. Efstathiou, MD, DPHIL

4:20 p.m. – 5:00 p.m.  High-Risk T3b with Lymphovascular Invasion

4:20 p.m. – 4:30 p.m.  Pathologic Determinants of High Risk Disease  Hikmat Al-Amadie, MD

4:30 p.m. – 4:40 p.m.  Neoadjuvant Chemotherapy for Cisplatin Eligible Patients and Management of Patients with Egfr < 50  Dan P. Petrylak, MD

4:40 p.m. – 4:50 p.m.  Management of No Response and/or Progression after Two Neoadjuvant Cycles  Eila C. Skinner, MD

5:00 p.m. – 5:15 p.m.  Questions and Closing

SALUTARY, MAY 17, 2014
SUO/SBUR Joint Meeting (Morning Program)  Orange County Convention Center  Location: W 330  7:50 a.m. – 11:30 a.m.

SUO Business Meeting Luncheon (Members Only)  Orange County Convention Center  Location: W 340 BCD  11:30 a.m. – 12:30 p.m.

SUO Annual Meeting (Afternoon Program)  Orange County Convention Center  Location: W 330  12:30 p.m. – 5:15 p.m.

SUO Reception and Dinner  Hyatt Regency Orlando  Location: Regency Grand Ballroom O  Attire: Business  6:00 p.m. – 10:00 p.m.
SUO/SBUR Joint Meeting Educational Needs (Morning Program)

The joint SUO/SBUR Meeting is focused on “The New Landscape of Therapy for Advanced Prostate Cancer” and will specifically address educational needs concerning: 1) New Insights Into The Androgen Axis In Advanced Prostate Cancer, and 2) Non-hormonal CRPC: New Mechanisms and Therapeutics.

Advances in the understanding of the pathobiology of CRPC lead to the improved treatment of patients with the disease. The first session will focus on androgen receptor-mediated mechanisms active under hormone ablation therapy, including intracrine androgen production, androgen receptor splice variants, and androgen receptor N-terminal inhibitors, and other resistance mechanisms. The second session will focus on new topics in the treatment of non-hormonally driven CRPC, including targeting long non-coding RNA regulation of the androgen receptor, the use of immunotherapy, the identification of prostate cancer subtypes such as small cell carcinoma of the prostate, the use of clinical and molecular predictors of survival in men with CPCT. The session will end with questions and case discussions focused on the integration, sequencing, and cross-relation of new systemic therapies for CRPC.

Discussion between leading urologists and basic scientists will reveal practice and educational gaps in the understanding of CRPC pathobiology and treatment. To overcome these gaps, first they must be identified and then followed by collaboration and translational research in order to ultimately improve the clinical management of CRPC.

SUO/ SBUR Educational Objectives (Morning Program)

At the conclusion of the session, participants should be able to:

1. Understand hormonal and non-hormonal regulation of androgen receptor activity.
2. Learn about the potential mechanisms underlying the development of CRPC.
3. Identify and discuss new therapeutic targets effective against CRPC.
4. Produce a platform for urologists and basic urological scientists to discuss the use of different therapeutic approaches, alone or in combination, to treat CRPC.
5. Identify how cancer can be described using ecological science principles.
6. Discover how cancer cells and host cells interact to promote cancer growth.

SUO Annual Meeting at the AUA Educational Needs (Afternoon Program)

- Deficit in knowledge about cumulative risks of routine radiologic imaging
- Deficit in performance regarding appropriate use of nuclear imaging studies for cancer surveillance
- Deficit in competence regarding treatment of RCC such that renal preservation remains underutilized
- Deficit in knowledge of optimal management of micropapillary urothelial carcinoma
- Deficit in knowledge of risks and benefits of intermittent vs continuous androgen blockade, particularly in light of recent clinical trials.

SUO Annual Meeting at the AUA Educational Objectives (Afternoon Program)

At the conclusion of the meeting attendees should be able to:
1. Identify new approaches to managing high risk prostate cancer.
2. Describe the treatment implications of renal cancer heterogeneity and the biology underlying this finding.
3. Demonstrate an understanding of the pathologic determinants of high risk bladder cancer.
4. Determine the role of neoadjuvant and adjuvant therapy for bladder cancer.

Credit Designation: The American Urological Association designates this live activity of the Society for Basic Urologic Research/Society of Urologic Oncology, Inc. Joint Meeting for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation: The American Urological Association designates this live activity for the Society of Urologic Oncology Afternoon Session for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The American Urological Association complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MARK YOUR CALENDAR

15th Annual Meeting of the Society of Urologic Oncology
Wednesday, December 3 – Friday, December 5, 2014

YUO Dinner: Wednesday, December 3rd
SUO Annual Banquet: Thursday, December 4th

Bethesda North Marriott Hotel & Conference Center
5701 Marinelli Road
Bethesda, MD 20852
Phone: (301) 822-9200
Fax: (301) 822-9201

SUO is happy to provide discounted room rates of $209.00, plus applicable tax at the host hotel. The block may sell out prior to the hotel deadline of November 11, 2014; therefore attendees are strongly encouraged to make early reservations.

Visit our website at www.suonet.org for updates on the program agenda and meeting registration.

SUBMIT YOUR ABSTRACT TODAY!

CALL FOR ABSTRACTS: May 12, 2014
ABSTRACTS DEADLINE: August 15, 2014
SUO held in conjunction with the AUA Annual Meeting
Saturday, May 4, 2013
Manchester Grand Hyatt San Diego
Elizabeth A – D
San Diego, CA

The morning session is a combined meeting of the Society of Urologic Oncology (SUO) and the Society of Basic Urologic Research (SBUR).

SUO/SBUR JOINT MEETING (MORNING PROGRAM)
Location: Elizabeth A – D

Targets and Therapies
7:55 a.m. – 8:00 a.m.
Introduction and Welcome
Marianne Sadar, PhD
BC Cancer Agency
Edward M. Messing, MD
University of Rochester

I. IMMUNOBASED STRATEGIES FOR TREATMENT OF UROLOGICAL MALIGNANCY
Moderator: Edward Messing, MD
8:00 a.m. – 8:20 a.m.
DNA Vaccines as Targeted Therapy for Prostate Cancer
Douglas McNeel, MD, PhD
Wisconsin Institute of Medical Research

8:20 a.m. – 8:25 a.m.
Questions & discussion

8:25 a.m. – 8:45 a.m.
Investigating Immune Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma
Padmanee Sharma, MD, PhD
MD Anderson Cancer Center

8:45 a.m. – 8:50 a.m.
Questions & discussion

8:50 a.m. – 9:10 a.m.
Molecular Grenades for Metastatic Prostate Cancer
John T. Isaacs, PhD
Johns Hopkins University School of Medicine

9:10 a.m. – 9:15 a.m.
Questions & discussion

II. FROM DISCOVERING TARGETS TO DEVELOPING THERAPIES
Moderator: Marianne Sadar, PhD
9:15 a.m. – 9:35 a.m.
Modulating Dendritic Responses in the Tumor Microenvironment Enhances Cancer Therapeutics
Peter Nelson, MD
University of Washington

9:35 a.m. – 9:40 a.m.
Questions & discussion

9:40 a.m. – 10:00 a.m.
Targeting EZH2 in Expression-Resistant Prostate Cancer
Myles A. Brown, MD
Harvard Medical School

10:00 a.m. – 10:05 a.m.
Questions & discussion

10:05 a.m. – 10:20 a.m.
NR4A Nuclear Receptors as
Thank you to the SUO 2013 – 2014 Corporate Sponsors

Janssen Biotech, Inc.
Medivation/Astellas